Detection of Hypermethylated Fibrillin-1 in the Stool Samples of Colorectal Cancer Patients

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2013 Aug 22

PMID 23963856

Citations 31

Authors

Qi Guo

Yongchun Song

Hao Zhang

Xuandi Wu

Peng Xia

Chengxue Dang

Affiliations

Soon will be listed here.

Abstract

Prior studies have demonstrated that analysis of gene promoter methylation in stool samples may be a potential biomarker for noninvasive colorectal cancer detection. Aberrant methylation in gene promoter is common in various cancers, and epigenetic alterations can result in down-regulation or silence of gene expression. Recently, hypermethylation of fibrillin-1 (FBN1) was reported to be associated with colorectal cancer (CRC). In this study, we examined the methylation status of FBN1 in stool samples to test CRC. For the purpose of colorectal cancer detection, we investigated FBN1 hypermethylation in the tissue and stool samples of colorectal cancer patients using methylation-specific polymerase chain reaction. The result is that out of 75 patients with colorectal cancer, 59 (78.7%) exhibited hypermethylated FBN1 in their tumor tissue DNA. We next detected the methylation status of FBN1 in the stool DNA of these patients. The hypermethylated FBN1 occurred in 72% (54/75) of these patients in their stool samples and occurred in 6.7% (2/30) of healthy people (P < 0.001). The results indicated 72.0% sensitivity and 93.3% specificity of the test for detecting CRC by using stool samples. So, the study reveals that hypermethylation status in the promoter of FBN1 is a high specific and sensitive biomarker for colorectal cancer, and detecting hypermethylated FBNI in stool samples is a noninvasive and useful method for screening colorectal cancer.

Citing Articles

The extracellular matrix glycoprotein fibrillin-1 in health and disease.

Li L, Huang J, Liu Y Front Cell Dev Biol. 2024; 11:1302285.

PMID: 38269088 PMC: 10806136. DOI: 10.3389/fcell.2023.1302285.

Role of fibrilins in human cancer: A narrative review.

Mahdizadehi M, Jazi M, Mir S, Jafari S Health Sci Rep. 2023; 6(7):e1434.

PMID: 37469709 PMC: 10353528. DOI: 10.1002/hsr2.1434.

Pre-diagnostic blood biomarkers for adult glioma.

Andrews L, Davies P, Herbert C, Kurian K Front Oncol. 2023; 13:1163289.

PMID: 37265788 PMC: 10229864. DOI: 10.3389/fonc.2023.1163289.

Epigenetic Regulations of Perineural Invasion in Head and Neck Squamous Cell Carcinoma.

Hurnik P, Chyra Z, Sevcikova T, Stembirek J, Smesny Trtkova K, Gaykalova D Front Genet. 2022; 13:848557.

PMID: 35571032 PMC: 9091179. DOI: 10.3389/fgene.2022.848557.

New Studies of the Aberrant Alterations in Fibrillin-1 Methylation During Colorectal Cancer Development.

Lv L, Ma J, Wu L, Zhang C, Wang Y, Wang G Front Oncol. 2022; 12:862887.

PMID: 35515111 PMC: 9067271. DOI: 10.3389/fonc.2022.862887.

References

Ostwald C, Linnebacher M, Weirich V, Prall F . Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol. 2009; 35(2):321-7. View

Zhang H, Song Y, Dang C . Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int J Med Sci. 2013; 10(3):230-4. PMC: 3558710. DOI: 10.7150/ijms.5278. View

Hellebrekers D, Lentjes M, van den Bosch S, Melotte V, Wouters K, Daenen K . GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 2009; 15(12):3990-7. DOI: 10.1158/1078-0432.CCR-09-0055. View

Dong J, Bu J, Du W, Li Y, Jia Y, Li J . A new novel mutation in FBN1 causes autosomal dominant Marfan syndrome in a Chinese family. Mol Vis. 2012; 18:81-6. PMC: 3261084. View

Nakayama H, Hibi K, Taguchi M, Takase T, Yamazaki T, Kasai Y . Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett. 2002; 188(1-2):115-9. DOI: 10.1016/s0304-3835(01)00839-4. View

Sanchez-Cespedes M, Esteller M, Wu L, Yoo G, Koch W, Jen J . Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000; 60(4):892-5. View

Lind G, Danielsen S, Ahlquist T, Merok M, Andresen K, Skotheim R . Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer. 2011; 10:85. PMC: 3166273. DOI: 10.1186/1476-4598-10-85. View

Hardcastle J, Chamberlain J, Robinson M, Moss S, Amar S, Balfour T . Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996; 348(9040):1472-7. DOI: 10.1016/S0140-6736(96)03386-7. View

Osborn N, Ahlquist D . Stool screening for colorectal cancer: molecular approaches. Gastroenterology. 2005; 128(1):192-206. DOI: 10.1053/j.gastro.2004.10.041. View

10.

Hellebrekers D, Melotte V, Vire E, Langenkamp E, Molema G, Fuks F . Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 2007; 67(9):4138-48. DOI: 10.1158/0008-5472.CAN-06-3032. View

11.

Bosch L, Mongera S, Terhaar Sive Droste J, Oort F, van Turenhout S, Penning M . Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection. Cell Oncol (Dordr). 2012; 35(4):309-15. DOI: 10.1007/s13402-012-0092-6. View

12.

Klaassen C, Jeunink M, Prinsen C, Ruers T, Tan A, Strobbe L . Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem. 2003; 49(7):1185-7. DOI: 10.1373/49.7.1185. View

13.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

14.

Vogelstein B, Kinzler K . Digital PCR. Proc Natl Acad Sci U S A. 1999; 96(16):9236-41. PMC: 17763. DOI: 10.1073/pnas.96.16.9236. View

15.

Ahlquist D, Skoletsky J, Boynton K, Harrington J, Mahoney D, Pierceall W . Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000; 119(5):1219-27. DOI: 10.1053/gast.2000.19580. View

16.

Zou H, Yu B, Wang Z, Sun J, Cang H, Gao F . Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res. 2002; 8(1):188-91. View

17.

Ahlquist D, Wieand H, MOERTEL C, MCGILL D, Loprinzi C, Oconnell M . Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA. 1993; 269(10):1262-7. View

18.

Imperiale T, Ransohoff D, Itzkowitz S, Turnbull B, Ross M . Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004; 351(26):2704-14. DOI: 10.1056/NEJMoa033403. View

19.

Burt R, Barthel J, Dunn K, David D, Drelichman E, Ford J . NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010; 8(1):8-61. DOI: 10.6004/jnccn.2010.0003. View

20.

Kim M, Lee J, Sidransky D . DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010; 29(1):181-206. DOI: 10.1007/s10555-010-9207-6. View